Kymab Acquisition, Valuation, Funding & Investors

BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It’s a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Pacific Shuanglin Bio-pharmacy Co Ltd is engaged in the research, development, production, and marketing of blood products.

Anew Labs is a platform developer that builds artificial intelligence systems for identifying pharmaceutical compounds, such as predicting molecular shapes and designing antibodies, by combining computational work with laboratory validation targeting inflammatory diseases.

Kardigan is a cardiovascular-focused biotechnology company, founded in 2024 by former MyoKardia executives including CEO Tassos Gianakakos, developing therapies for primary and secondary cardiomyopathies and related heart conditions through what it calls a cardiac intelligence platform. Its pipeline includes danicamtiv, a cardiac myosin activator for genetic dilated cardiomyopathy in-licensed from Bristol Myers Squibb; tonlamarsen, an acute severe hypertension candidate from Ionis Pharmaceuticals; and ataciguat, a guanylate cyclase activator for calcific aortic valve stenosis acquired from Sanofi and Mayo Clinic. The company is headquartered in South San Francisco, California and Princeton, New Jersey.

Verdiva Bio is a San Diego-based biotechnology firm developing oral GLP-1 receptor agonists for obesity and cardiometabolic disorders. The company's lead candidate targets improved tolerability over injectables, with preclinical data showing enhanced weight loss in animal models. Verdiva advances therapies through partnerships with contract research organizations in California.

Moonlight Therapeutics is a biotechnology company developing oral immunotherapies for food allergies. Headquartered in Boston, the firm advances clinical-stage candidates targeting peanut, tree nut, and milk allergies through dissolvable tablets that build tolerance safely. Moonlight Therapeutics employs nanoparticle delivery for improved efficacy and patient adherence. Founded in 2021, it collaborates with academic institutions on phase II trials.

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others.

Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. The only reportable segment of the company is the Pharmaceuticals business segment, which engages mainly in the research and development, manufacturing and sales of pharmaceutical products. It has a geographic presence in the United States, Malta, Taiwan, and Others.

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team’s deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.